MacroGenics’ updated presentation reports MGC026 best overall response rate of 27% in late-line SCCHN, with 64% disease control rate, and $288M in cash and marketable securities supporting cash runway guidance through 2028.
MGNX · Macrogenics Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
MacroGenics held $287.7 million in cash, cash equivalents and marketable securities, with cash runway guidance through 2028. It reported a third-quarter net loss of $20.1 million, completed MGC028 dose escalation and dosed the first patient in MGC030’s Phase 1 study.
Macrogenics sold its CDMO Operations to Bora for a $122.5 million purchase price and received $119.6 million after adjustments, recognizing an $87.5 million pretax gain. Cash runway is expected through 2028, dependent on future partner payments and cost savings.
MacroGenics appointed Emil Kuriakose, M.D. and Michael Vasconcelles, M.D. as independent directors effective October 30, 2026, expanding its board from ten to eleven members.
MacroGenics reported interim Phase 1 MGC026 data showing a 27% best overall response rate in heavily pretreated SCCHN patients, with no treatment-related discontinuations, and plans an early 2027 front-line pembrolizumab combination cohort.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| cash consideration from Bora | $119.6M | During the third quarter | — |
| option license payment from Gilead | $10M | During the third quarter | — |
| regulatory milestone payment from Sanofi | $24.5M | During the third quarter | — |
| Income from operations of the CDMO Operations | $3M | the three months ended June 30, 2026 filing | — |
| Net gain on sale of the CDMO Operations | $86.1M | the three months ended June 30, 2026 filing | — |
| Pretax net gain on sale of CDMO Operations | $86.1M | the three months ended June 30, 2026 filing | — |
| Pro forma cash, cash equivalents and marketable securities | $327M | Q2 2026 | — |
| Shares of common stock outstanding | 63,645,711 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MGNX
this stock
Macrogenics Inc
|
$131.01M | +27.3% | -0.3% | — | 7.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$135.44B | +17.8% | +46.2% | 34.4 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$99.08B | +24.1% | +20.8% | 21.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.68B | +601.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$64.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 24
MacroGenics’ updated presentation reports MGC026 best overall response rate of 27% in late-line SCCHN, with 64% disease control rate, and $288M in cash and marketable securities supporting cash runway guidance through 2028.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MGNX | -15.3% | -41.3% | -51.3% | -14.6% | +27.3% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | -13.0% | -36.5% | -48.4% | -11.5% | +19.9% |